Walle A J, Niedermayer W
Cancer Detect Prev. 1985;8(1-2):303-15.
Aneuploidy as an indication of abnormal cellular DNA content has recently been confirmed to be a reliable marker of malignant cells in human solid tumors and hematologic malignancies. Flow cytometry (FCM), measuring cellular DNA content in thousands of cells within seconds, is able to safely detect the "rare event cell," the rare aneuploid cell in a diploid cell population. This very fast and sensitive technique was combined with a newly developed cell separation technique. Cell separation prior to FCM enabled us to detect malignant cells at concentrations of 0.05% in blood, bone marrow, and lymph node cell suspensions of patients with leukemia. An illustration of this method is presented in conjunction with first clinical applications demonstrating that patients with minimal residual disease in clinically complete remission had significantly shorter survival times than patients in whom no minimal residual disease was detected with this new method.
非整倍体作为细胞DNA含量异常的一种表现，最近已被确认为人类实体瘤和血液系统恶性肿瘤中恶性细胞的可靠标志物。流式细胞术（FCM）能在数秒内测量数千个细胞的DNA含量，能够安全地检测“稀有事件细胞”，即二倍体细胞群体中的稀有非整倍体细胞。这项非常快速且灵敏的技术与一种新开发的细胞分离技术相结合。在进行FCM之前进行细胞分离，使我们能够在白血病患者的血液、骨髓和淋巴结细胞悬液中检测到浓度低至0.05%的恶性细胞。结合首次临床应用展示了该方法，结果表明临床完全缓解但有微小残留病的患者的生存时间明显短于用这种新方法未检测到微小残留病的患者。
